Ovarian Serous Cystadenocarcinoma (DBCOND0028508)

Identifiers

Synonyms

Serous cystadenocarcinoma ovary

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	Bevacizumab Sapanisertib	treatment	1	active_not_recruiting
NCT00004221	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer	Carboplatin Cyclophosphamide Filgrastim Paclitaxel Topotecan	treatment	2	terminated
NCT01080521	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy	No drug interventions	Not Available	Not Available	completed
NCT01074411	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bortezomib Bortezomib D-mannitol Carboplatin	treatment	1	completed
NCT01294293	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Doxorubicin Motolimod Paclitaxel	treatment	1	completed
NCT01489371	EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Cholesterol Doxorubicin EGEN-001 Tetracycline	treatment	1	completed
NCT00939809	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Urokinase	treatment	2	completed
NCT00002913	Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer	Cisplatin Filgrastim Paclitaxel Topotecan	treatment	1	completed
NCT00993616	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin	Belinostat Carboplatin	treatment	2	completed
NCT02283658	Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Everolimus Letrozole	treatment	2	completed
NCT00053235	Research Study in Patients With Advanced Ovarian Epithelial Cancer	No drug interventions	Not Available	Not Available	withdrawn
NCT00814086	Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Cisplatin Paclitaxel	treatment	1	completed
NCT00079430	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	1	completed
NCT00357448	Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer	Denileukin diftitox Human interleukin-2	treatment	1	completed
NCT01492920	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	No drug interventions	supportive_care	3	withdrawn
NCT01459380	Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Bevacizumab Carboplatin Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT01275664	Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer	Aprepitant Carboplatin Chloride ion Cisplatin Dexamethasone Granisetron Platinum	supportive_care	Not Available	terminated
NCT00059787	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma	Carboplatin Erlotinib Paclitaxel	treatment	2	completed
NCT02050009	Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Metformin Paclitaxel	treatment	1	withdrawn
NCT02122185	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Metformin	treatment	2	active_not_recruiting
NCT00060359	Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer	Carboplatin Glutamic acid Paclitaxel poliglumex	treatment	1	completed
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Adavosertib Gemcitabine	treatment	2	active_not_recruiting
NCT00897442	Collecting Tumor Samples From Patients With Gynecological Tumors	No drug interventions	Not Available	Not Available	completed
NCT02111941	Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Folic acid	treatment	0	active_not_recruiting
NCT00085358	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)	Bevacizumab Carboplatin Docetaxel Paclitaxel	treatment	1	completed
NCT00466960	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy	Albumin human Paclitaxel Sargramostim	treatment	2	completed
NCT05074472	A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	ZB131	treatment	1 / 2	completed